D
Xenon Pharmaceuticals Inc.
XENE
$35.32
$0.140.40%
D
Sell
10/28/2024Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D on 10/28/2024 due to a decline in the total return index, solvency index and growth index. The quick ratio declined from 31.52 to 23.09, earnings per share declined from -$0.6177 to -$0.7458, and EBIT declined 17.04% from -$59.04M to -$69.1M.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D on 10/28/2024 due to a decline in the total return index, solvency index and growth index. The quick ratio declined from 31.52 to 23.09, earnings per share declined from -$0.6177 to -$0.7458, and EBIT declined 17.04% from -$59.04M to -$69.1M.
D
Sell
3/11/2024Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D from D- on 3/11/2024 due to a noticeable increase in the total return index, growth index and solvency index. Operating cash flow increased 16.02% from -$42.23M to -$35.47M, earnings per share increased from -$0.7342 to -$0.6395, and the quick ratio increased from 21.32 to 23.43.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D from D- on 3/11/2024 due to a noticeable increase in the total return index, growth index and solvency index. Operating cash flow increased 16.02% from -$42.23M to -$35.47M, earnings per share increased from -$0.7342 to -$0.6395, and the quick ratio increased from 21.32 to 23.43.
D
Sell
12/7/2023Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D on 12/7/2023 due to a major decline in the solvency index, total return index and growth index. Operating cash flow declined 27.12% from -$33.22M to -$42.23M, earnings per share declined from -$0.7206 to -$0.7342, and EBIT declined 0.11% from -$55.62M to -$55.68M.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D on 12/7/2023 due to a major decline in the solvency index, total return index and growth index. Operating cash flow declined 27.12% from -$33.22M to -$42.23M, earnings per share declined from -$0.7206 to -$0.7342, and EBIT declined 0.11% from -$55.62M to -$55.68M.
D
Sell
3/14/2023Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D from D+ on 3/14/2023 due to a decline in the total return index.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D from D+ on 3/14/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D- on 02/09/2023.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D- on 02/09/2023.
D
Sell
2/8/2023Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D+ on 2/8/2023 due to a noticeable decline in the growth index, total return index and solvency index. Operating cash flow declined 80.23% from -$16.87M to -$30.4M, total revenue declined 75.37% from $536 to $132, and the quick ratio declined from 57.57 to 41.23.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D+ on 2/8/2023 due to a noticeable decline in the growth index, total return index and solvency index. Operating cash flow declined 80.23% from -$16.87M to -$30.4M, total revenue declined 75.37% from $536 to $132, and the quick ratio declined from 57.57 to 41.23.
D
Sell
5/16/2022Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D- on 5/16/2022 due to a noticeable increase in the growth index and volatility index. Total revenue increased 134.57% from $3.74M to $8.77M, EBIT increased 30.07% from -$24.84M to -$17.37M, and earnings per share increased from -$0.4855 to -$0.3707.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D- on 5/16/2022 due to a noticeable increase in the growth index and volatility index. Total revenue increased 134.57% from $3.74M to $8.77M, EBIT increased 30.07% from -$24.84M to -$17.37M, and earnings per share increased from -$0.4855 to -$0.3707.
D
Sell
5/13/2022Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D+ on 5/13/2022 due to a noticeable decline in the total return index.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D+ on 5/13/2022 due to a noticeable decline in the total return index.
D
Sell
5/4/2022Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D- on 5/4/2022 due to an increase in the valuation index.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D- on 5/4/2022 due to an increase in the valuation index.
D
Sell
5/1/2022Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D+ on 05/01/2022.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D+ on 05/01/2022.
D
Sell
4/21/2022Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D- on 4/21/2022 due to an increase in the volatility index.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D- on 4/21/2022 due to an increase in the volatility index.
D
Sell
4/20/2022Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D+ on 4/20/2022 due to a decline in the valuation index.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D+ on 4/20/2022 due to a decline in the valuation index.
D
Sell
3/4/2022Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D on 3/4/2022 due to an increase in the valuation index, volatility index and solvency index. The quick ratio increased from 19.67 to 38.72.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D on 3/4/2022 due to an increase in the valuation index, volatility index and solvency index. The quick ratio increased from 19.67 to 38.72.
D
Sell
11/15/2021Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D from D- on 11/15/2021 due to an increase in the growth index, solvency index and total return index. Total revenue increased 266.28% from $2.22M to $8.12M, EBIT increased 30.67% from -$22.5M to -$15.6M, and earnings per share increased from -$0.5008 to -$0.3662.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D from D- on 11/15/2021 due to an increase in the growth index, solvency index and total return index. Total revenue increased 266.28% from $2.22M to $8.12M, EBIT increased 30.67% from -$22.5M to -$15.6M, and earnings per share increased from -$0.5008 to -$0.3662.
D
Sell
11/8/2021Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D on 11/08/2021.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D on 11/08/2021.
D
Sell
11/3/2021Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D from D+ on 11/3/2021 due to a decline in the valuation index and volatility index.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D from D+ on 11/3/2021 due to a decline in the valuation index and volatility index.
D
Sell
10/11/2021Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D on 10/11/2021 due to a large increase in the total return index and volatility index.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D on 10/11/2021 due to a large increase in the total return index and volatility index.
D
Sell
8/13/2021Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D from D+ on 8/13/2021 due to a significant decline in the total return index, growth index and solvency index. Total revenue declined 49.11% from $4.36M to $2.22M, EBIT declined 40.1% from -$16.06M to -$22.5M, and the quick ratio declined from 24.34 to 17.58.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D from D+ on 8/13/2021 due to a significant decline in the total return index, growth index and solvency index. Total revenue declined 49.11% from $4.36M to $2.22M, EBIT declined 40.1% from -$16.06M to -$22.5M, and the quick ratio declined from 24.34 to 17.58.
D
Sell
5/12/2021Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D on 5/12/2021 due to a major increase in the total return index, solvency index and valuation index. The quick ratio increased from 12.1 to 24.34.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D on 5/12/2021 due to a major increase in the total return index, solvency index and valuation index. The quick ratio increased from 12.1 to 24.34.
D
Sell
3/3/2021Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D from D+ on 3/3/2021 due to a decline in the valuation index, solvency index and volatility index.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D from D+ on 3/3/2021 due to a decline in the valuation index, solvency index and volatility index.
D
Sell
1/5/2021Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D on 1/5/2021 due to a noticeable increase in the total return index and volatility index.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D on 1/5/2021 due to a noticeable increase in the total return index and volatility index.
D
Sell
11/10/2020Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D from D+ on 11/10/2020 due to a significant decline in the growth index, total return index and valuation index. Earnings per share declined from -$0.0049 to -$0.2602, EBIT declined 1,401.39% from -$646 to -$9.7M, and total revenue declined 51.03% from $13.38M to $6.55M.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D from D+ on 11/10/2020 due to a significant decline in the growth index, total return index and valuation index. Earnings per share declined from -$0.0049 to -$0.2602, EBIT declined 1,401.39% from -$646 to -$9.7M, and total revenue declined 51.03% from $13.38M to $6.55M.
D
Sell
5/22/2020Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D on 5/22/2020 due to a significant increase in the growth index, solvency index and valuation index. Total revenue increased 112.62% from $3.33M to $7.08M, debt to equity declined from 0.19 to 0.09, and earnings per share increased from -$0.4144 to -$0.2188.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D+ from D on 5/22/2020 due to a significant increase in the growth index, solvency index and valuation index. Total revenue increased 112.62% from $3.33M to $7.08M, debt to equity declined from 0.19 to 0.09, and earnings per share increased from -$0.4144 to -$0.2188.
D
Sell
8/9/2018Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D from D- on 8/9/2018 due to a significant increase in the total return index, volatility index and growth index. Operating cash flow increased 32.62% from -$8.22M to -$5.54M, and EBIT increased 2.97% from -$7.82M to -$7.59M.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D from D- on 8/9/2018 due to a significant increase in the total return index, volatility index and growth index. Operating cash flow increased 32.62% from -$8.22M to -$5.54M, and EBIT increased 2.97% from -$7.82M to -$7.59M.
D
Sell
2/12/2018Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D- from E+ on 2/12/2018 due to an increase in the total return index and volatility index.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D- from E+ on 2/12/2018 due to an increase in the total return index and volatility index.
E
Sell
10/25/2017Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to E+ from D- on 10/25/2017 due to a decline in the efficiency index, total return index and volatility index. Total capital declined 11.79% from $57.2M to $50.45M.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to E+ from D- on 10/25/2017 due to a decline in the efficiency index, total return index and volatility index. Total capital declined 11.79% from $57.2M to $50.45M.
D
Sell
5/10/2017Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D on 5/10/2017 due to a noticeable decline in the efficiency index and total return index. Net income declined 25.2% from -$6M to -$7.52M, and total capital declined 10.49% from $63.9M to $57.2M.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D on 5/10/2017 due to a noticeable decline in the efficiency index and total return index. Net income declined 25.2% from -$6M to -$7.52M, and total capital declined 10.49% from $63.9M to $57.2M.
D
Sell
8/22/2016Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D from D- on 8/22/2016 due to an increase in the total return index and volatility index.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D from D- on 8/22/2016 due to an increase in the total return index and volatility index.
D
Sell
8/5/2016Downgrade
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D on 8/5/2016 due to a major decline in the efficiency index, volatility index and growth index. Net income declined 84.37% from -$3.26M to -$6.02M, earnings per share declined from -$0.2267 to -$0.4175, and total revenue declined 31.28% from $601 to $413.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to D- from D on 8/5/2016 due to a major decline in the efficiency index, volatility index and growth index. Net income declined 84.37% from -$3.26M to -$6.02M, earnings per share declined from -$0.2267 to -$0.4175, and total revenue declined 31.28% from $601 to $413.
D
Sell
12/1/2015Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D from D- on 12/1/2015 due to an increase in the solvency index. The quick ratio increased from 6.15 to 12.32.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D from D- on 12/1/2015 due to an increase in the solvency index. The quick ratio increased from 6.15 to 12.32.
D
Sell
8/3/2015Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D- from E+ on 8/3/2015 due to an increase in the valuation index.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to D- from E+ on 8/3/2015 due to an increase in the valuation index.
E
Sell
5/1/2015Upgraded
Xenon Pharmaceuticals Inc. (XENE) was upgraded to E+ from E on 5/1/2015 due to a significant increase in the solvency index, total return index and valuation index. The quick ratio increased from 2.94 to 5.9.
Xenon Pharmaceuticals Inc. (XENE) was upgraded to E+ from E on 5/1/2015 due to a significant increase in the solvency index, total return index and valuation index. The quick ratio increased from 2.94 to 5.9.
E
Sell
2/2/2015None
Xenon Pharmaceuticals Inc. (XENE) was downgraded to E from U on 02/02/2015.
Xenon Pharmaceuticals Inc. (XENE) was downgraded to E from U on 02/02/2015.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
